At a glance
ClinicalIndex Comparison RecordPhase 2Active· 250 target
Drug / intervention
Cytarabine +1 moredrug
Likely dose
Cytarabine 3gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT03031262Phase 2ActiveUpdate OverdueUpdated 13mo ago · Completion was 14mo agoEnrollment Stalled
Efficacy and Safety of Chidamide in CBF Leukemia
Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Jan 25, 2017·Updated May 30, 2025
In Brief
A Phase 2 clinical trial evaluating Cytarabine and Chidamide for AML. Active but no longer recruiting, targeting 250 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAML
CountriesChina
Collaborators--
Timeline
Phase 2Active
201720182019202020212022202320242025202620272028
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionApr 2025
TodayJul 2026
Study CompletionDec 2027
First PostedJan 25, 2017
Enrollment StartFeb 8, 2017
Primary CompletionApr 10, 2025
Study CompletionDec 30, 2027
TodayJul 1, 2026
Enrollment to primary: 8.2 yearsPosted 9.4 years ago
Interventions
Cytarabinedrug
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Chidamidedrug
Chidamide at a dose of 20mg/d twice a week for 3 months.